home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

New Immune Cell Exit Strategy

  March, 8 2007 8:14
your information resource in human molecular genetics
Immune cells recruited to sites of infection can use more than one type of molecule to exit the bloodstream, according to a paper published in the April 2007 issue of Nature Immunology. The discovery may have implications for researchers seeking to treat inflammatory diseases by blocking lymphocyte entry into damaged tissues.

Traveling at the speed of blood flow, immune cells called lymphocytes are whisked rapidly through blood vessels. After infection or injury, they travel to the site of damage, and thus need to exit the blood vessel highway. Lymphocytes use a protein called L-selectin to recognize and grasp onto specific types of complex sugars called O-glycans displayed on inflamed blood vessel walls.

Minoru Fukuda and colleagues showed that, in mice, lymphocytes also recognize exit signs on sugars called N-glycans. Whether human lymphocytes behave similarly remains to be seen. If they do, researchers seeking to treat inflammatory diseases need to target more than one lymphocyte exit strategy.

Author contact:

Minoru Fukuda (Burnham Institute for Medical Research, La Jolla, CA, USA)
E-mail: minoru@burnham.org

Abstract available online.

(C) Nature Immunology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.